Palau Pharma (worldwide rights to lbaconazole development product) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Palau Pharma (worldwide rights to lbaconazole development product) General Information

Description

Worldwide rights to Palau Pharma's Albaconazole development product. The drug is an oral antifungal agent for the treatment of vulvo-vaginal candidiasis, onychomycosis and other antifungal applications.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Other Commercial Services
Pharmaceuticals
Acquirer
Primary Office
  • Pol. Ind. Riera de Caldes Avinguda Camí Reial 51-57
  • Palau-solità i Plegamans
  • 08184 Barcelona
  • Spain
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Palau Pharma (worldwide rights to lbaconazole development product) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Palau Pharma (worldwide rights to lbaconazole development product)‘s full profile, request access.

Request a free trial

Palau Pharma (worldwide rights to lbaconazole development product) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Palau Pharma (worldwide rights to lbaconazole development product)‘s full profile, request access.

Request a free trial